TY - JOUR
T1 - Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial
AU - Belani, Chandra
AU - Pereira, Jose R.
AU - von Pawel, Joachim
AU - Pluzanska, Anna
AU - Gorbounova, Vera
AU - Kaukel, Eckhard
AU - Mattson, Karin V.
AU - Ramlau, Rodryg
AU - Szczesna, Aleksandra
AU - Fidias, Panos
AU - Millward, Michael
AU - Fossella, Frank
N1 - Funding Information:
We are indebted to Francis C. Gamza, MD, Jocelyne Berille, MD, and Yong S. Kim, PhD (statistician) for planning and implementing the study; Antoinette Wozniak, MD, Lionel Bosquee, MD, and Claude Ramazeilles, PhD for their valuable insights; Luz Hammershaimb, MD, Antoine Yver, MD, and Jean-Pierre Bizzari, MD for their support of the study; Richard Gralla, MD for assistance with data analyses; Mark R. Green, MD (Chair), Lucio Crino, MD, and Boris Iglewicz, PhD from the independent data monitoring committee; to Wendy Crist (international study manager), Isabelle Dancy, PhD (study manager), Anthony Rodgers, PhD (statistician), Martin Roessner, MSc (statistician), James Stephens (statistician), Sandrine Anneheim-Herbelin, PhD (study manager), and Jean-Luc Schmidt (data manager). All authors confirm that they have not received payment for writing this article. The study was funded by Aventis Pharmaceuticals, a member of the sanofi-aventis Group. The sponsor provided assistance with study management, data collection, statistical analysis, and editorial support.
PY - 2006/8
Y1 - 2006/8
N2 - Background: Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve quality of life (QoL). We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin. Methods: QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and the general EuroQol five-dimensional questionnaire (EQ-5D) in 926 chemotherapy-naïve patients with stages IIIB to IV NSCLC. Patients were randomly assigned to receive: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb); or vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC). Results: Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P = 0.064 for DC and P = 0.016 for DCb versus VC; EQ-5D global item "health state today": P = 0.016 for DC and P < 0.001 for DCb versus VC). DC-treated patients experienced improved pain relief compared with VC (P = 0.033), whereas pain relief with DCb and VC was similar. Patients treated with either docetaxel regimen had more favorable changes in performance status (P = 0.065 for DC and P < 0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P < 0.001 for both DC versus VC and DCb versus VC). Conclusion: The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.
AB - Background: Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve quality of life (QoL). We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin. Methods: QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and the general EuroQol five-dimensional questionnaire (EQ-5D) in 926 chemotherapy-naïve patients with stages IIIB to IV NSCLC. Patients were randomly assigned to receive: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb); or vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC). Results: Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P = 0.064 for DC and P = 0.016 for DCb versus VC; EQ-5D global item "health state today": P = 0.016 for DC and P < 0.001 for DCb versus VC). DC-treated patients experienced improved pain relief compared with VC (P = 0.033), whereas pain relief with DCb and VC was similar. Patients treated with either docetaxel regimen had more favorable changes in performance status (P = 0.065 for DC and P < 0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P < 0.001 for both DC versus VC and DCb versus VC). Conclusion: The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.
UR - http://www.scopus.com/inward/record.url?scp=33745893529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745893529&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2006.05.003
DO - 10.1016/j.lungcan.2006.05.003
M3 - Article
C2 - 16787687
AN - SCOPUS:33745893529
VL - 53
SP - 231
EP - 239
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 2
ER -
